FDA
Pharma

2 FDA citations trouble Hengrui, Elevar’s liver cancer combo

Following resolution of the problem cited in the CRL, investors questioned why the FDA issued a swift rejection instead of waiting for the PDUFA date.
Angus Liu Jul 28, 2026 3:02pm
The CSO Model Is Endangered Heres How Contract Field Organizations Must Evolve to Survive

The CSO Model Is Endangered. Here’s How to Evolve.

Brought to you by Mix Talent
Johnson Johnsons Baby Powder

J&J proposes $5.5B deal to resolve 76,000 ovarian cancer claims

Jul 28, 2026 11:26am
Magnifying glass with pills on blue

Regulatory tracker: MannKind's edema autoinjector nets FDA nod

Jul 28, 2026 10:20am
Miels

GSK CEO targets mature products, procurement for cost savings

Jul 28, 2026 9:45am
Screengrab of Gileads up to date HIV campaign

Gilead uses humor in ‘Up to Date’ HIV prevention push

Jul 28, 2026 8:00am
More News

Havas Lynx revamps New York C-suite 16 months after last shakeup

Jul 28, 2026 3:52am

FDA approves Otsuka’s first-in-class ADHD drug Simtriyo

Jul 27, 2026 12:42pm

After 3 CRLs, FDA approves Outlook's AMD drug Lytenava

Jul 27, 2026 11:51am

Sarepta taps AbbVie vet Severino to take over for retiring CEO

Jul 27, 2026 11:36am